A comprehensive welfare analysis of canine lymphoma, the most common hematopoietic cancer in dogs, including treatment options, quality of life, and end-of-life care.
Key Facts
Canine lymphoma (malignant lymphoma, lymphosarcoma) is the most common hematopoietic malignancy in dogs — it accounts for 7-24% of all canine cancers and has an annual incidence of approximately 24 per 100,000.
Multicentric lymphoma is the most common form — dogs present with rapidly enlarging peripheral lymph nodes (submandibular, prescapular, popliteal), often discovered incidentally by owners.
Without treatment, median survival is 4-6 weeks after diagnosis — many owners are unaware of the rapid progression and delay seeking treatment.
CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisolone) achieves remission in 75-90% of dogs — median survival with treatment is 12-18 months.
Quality of life during CHOP chemotherapy is generally good — dogs typically experience only mild side effects (occasional vomiting, lethargy) and most maintain normal activity between cycles.
Relapse occurs in most dogs — second-line protocols (MOPP, LOPP, lomustine) may achieve further remission, but durations shorten with each relapse.
End-of-life planning should begin at diagnosis — establishing goals of care (curative vs. palliative intent), quality of life thresholds, and euthanasia criteria enables compassionate decision-making.
Welfare Considerations
Canine lymphoma is serious and ultimately incurable, but treatment with CHOP chemotherapy offers good quality of life and meaningful extra time for most dogs. The welfare argument for treatment is strong — dogs on chemotherapy feel well between treatments and experience relatively few side effects. Early diagnosis and prompt treatment start maximize welfare outcomes. End-of-life discussions should begin at diagnosis, not at relapse.
What You Can Do
Seek veterinary assessment promptly for any dog with rapidly enlarged lymph nodes — early diagnosis improves treatment outcomes
Consider CHOP chemotherapy — most dogs tolerate it well and it provides the best quality of life extension
Establish quality-of-life thresholds and euthanasia criteria at diagnosis to guide compassionate end-of-life decisions
Support Morris Animal Foundation and AKC Canine Health Foundation lymphoma research